ClinicalTrials.gg
CompletedNCT07404306Updated Feb 23, 2026

Part 1: Dose-Finding of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users

A Phase 1 interventional study of HSK3486 and propofol in General Anesthesia, sponsored by Haisco-USA Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-23.

Sponsored by Haisco-USA Pharmaceuticals, Inc. (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2023, 3 years 1 month ago, and no results have been posted to the registry.
  • Registered 3 years 5 months after the study started (first participant enrolled Aug 2022, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Part 1: To determine the doses of IV HSK3486 and propofol for use in Part 2, the abuse potential part of the study.

Part 2: To evaluate the abuse potential of HSK3486 compared with propofol when administered IV to healthy nondependent, recreational CNS depressant drug users.

Read the detailed description

This single center study will consist of 2 parts. Part 1 will be an open-label, dose-finding study of HSK3486 and propofol conducted in up to 48 recreational users of CNS depressants to determine the appropriate doses to be used in Part 2 of the study. Part 2 will be a randomized, double-blind, placebo- and active-controlled 4-period, 4 way crossover, in approximately 42 healthy volunteers with prior recreational CNS depressant exposure. Both Part 1 and Part 2 of the study will consist of an outpatient Screening Visit, an in-clinic Treatment Phase, and Follow-up; Part 2 will also include a Qualification Phase.

02

Conditions studied

  • General Anesthesia
03

In context

Lead sponsor

Haisco-USA Pharmaceuticals, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The following criteria must be met for a subject to be eligible for inclusion in the study:

  1. Willing to participate in the study, give written , and comply with the study restrictions.
  2. Gender: male or female; females may be of , of nonchildbearing potential, or .
  3. Age: 18 years to 55 years, inclusive, at Screening.
  4. (BMI): 18.0 kg/m2 to 30.0 kg/m2, inclusive.
  5. Weight: ≥50 kg, inclusive.
  6. Healthy subject, defined by the absence of evidence of any , in the opinion of the Investigator, active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead , hematology, blood chemistry, serology, and urinalysis.
  7. Subject must be a nondependent, nontreatment-seeking recreational CNS depressant user, defined as follows:

    1. ≥10 lifetime nontherapeutic experiences (i.e., for psychoactive effects) with CNS depressants (e.g., benzodiazepines, barbiturates, opiates, zolpidem, zopiclone, propofol/fospropofol, gamma-hydroxybutyrate).
    2. ≥1 nontherapeutic use of a CNS depressant within the 8 weeks prior to screening.
    3. ≥1 nontherapeutic use of benzodiazepines within the 12 months prior to screening.
  8. Ability and willingness to abstain from alcohol-, caffeine-, and xanthine-containing beverages or food (e.g., coffee, tea, cola, chocolate, energy drinks) from 48 hours (2 days) prior to first admission to the CRU, throughout the entire study, and until discharge.
  9. All values for hematology and clinical chemistry tests of blood and urine within the normal range or show no clinically relevant deviations, as judged by the Investigator.
  10. Females of childbearing potential, and males with female partner(s) of childbearing potential, as judged by the Investigator, must agree to use 2 forms of , 1 of which must be a barrier method, during the study and for 90 days after the last drug administration. Acceptable barrier forms of contraception are condom, cervical cap, and diaphragm. Acceptable non barrier forms of contraception for this study are an intrauterine device (IUD) including hormonal IUDs, oral contraceptives (used for ≥30 days prior to dosing any study treatment), and/or spermicide.
  11. For females: a negative pregnancy test at Screening and Admission.
  12. Postmenopausal females: defined as 12 months with no menses prior to Screening and a serum follicle stimulating hormone (FSH) >40 IU/L at Screening.
  13. All nonregular medication (including over-the-counter medication, health supplements, and herbal remedies such as St. John's Wort extract) must have been stopped at least 14 days prior to (the first) admission to the CRU. An exception is made for acetaminophen, which is allowed up to admission to the CRU.
  14. All prescribed medication must have been stopped at least 30 days prior to (first) admission to the clinical research center. An exception is made for hormonal contraceptives, which may be used throughout the study.
  15. Able to speak, read, and understand English sufficiently to allow completion of all study assessments.

Exclusion criteria

Exclusion Criteria:

A subject who meets any of the following criteria will not be eligible for inclusion in the study:

  1. An employee of the Sponsor or research site personnel directly affiliated with this study or their immediate family member (defined as a spouse, parent, child, or sibling, whether biological or legally adopted).
  2. Drug or alcohol dependence within the 2 years prior to Screening (except nicotine and caffeine), as defined by the , fourth edition, text revision (DSM-IV-TR), and/or has ever participated or plans to participate in a substance or alcohol rehabilitation program to treat their substance or alcohol dependence.
  3. Opioid dependence as judged by the Investigator after a naloxone challenge.
  4. Women who are pregnant, lactating, or planning to attempt to become pregnant during this study or within 90 days of last study drug administration.
  5. Males with female partners who are pregnant, lactating, or planning to attempt to become pregnant during this study or within 90 days of last study drug administration.
  6. Positive drug and alcohol screen (tetrahydrocannabinol [THC], morphine/opiates, methadone, oxycodone, phencyclidine, cocaine, amphetamines, methamphetamines, ecstasy, barbiturates, benzodiazepines, tricyclic antidepressants, and alcohol) at each admission to the CRU. For THC, subjects should ideally test negative. However, eligibility decision with regards to THC use will be considered on a case by case basis, at the discretion of the Investigator.
  7. Treatment with an drug or device within 5 times the elimination half-life, if known (e.g., a marketed product) or within 30 days (if the elimination half-life is unknown) prior to first drug administration or is concurrently enrolled in any research judged not to be scientifically or medically compatible with this study. An exception may be made for subjects who participated in Part 1 of the study.
  8. History or presence of abnormality (e.g., obstructive sleep apnea) as assessed by physical examination, medical history, , vital signs, or laboratory values, which, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.
  9. Any disease which, in the opinion of the Investigator, poses an unacceptable risk to the subjects.
  10. Mallampati intubation score >2.
  11. History of clinically significant drug allergy diagnosed by a physician. Confirmatory circumstances would include treatment with epinephrine or in an emergency department.
  12. Any personal or family history of issues with succinylcholine, such as malignant hyperthermia or pseudocholinesterase deficiency.
  13. History of allergy, adverse reaction (including significant agitation, etc.), or to propofol, lidocaine, other injected anesthetic agents, or related drugs.
  14. History of allergy to eggs, egg products, soybeans or soy products.
  15. Heavy smoker (>20 cigarettes per day) and/or is unable to abstain from smoking and/or the use of prohibited nicotine-containing products (including e-cigarettes, pipes, cigars, chewing tobacco, nicotine topical patches, nicotine gum, or nicotine lozenges) from 2 hours prior to dosing until at least 4 hours postdose during the in-clinic periods.
  16. Routine or chronic use of more than 3000 mg of acetaminophen daily.
  17. Strenuous activity (such as exercise), sunbathing, and contact sports within 48 hours (2 days) prior to admission to the CRU, during the study, and until after discharge in the last study period.
  18. History of donation of more than 450 mL of blood within 60 days prior to dosing in the CRU or planned donation before 30 days has elapsed since last intake of study drug.
  19. Plasma or donation within 7 days of dosing and throughout the entire study.
  20. Average intake of more than 14 units of alcohol per week (1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine, or 35 mL of spirits). Alcohol consumption will be prohibited 48 hours prior to first admission to the CRU and throughout the entire study until the Follow-up visit (including ).
  21. Positive screening test for surface antigen (HBsAg), anti- virus (HCV) antibodies, or anti- 1 and 2 antibodies.
  22. History of peripheral vasculopathy, including Raynaud's phenomenon.
  23. History of seizures, seizure disorder, or known electroencephalogram (EEG) abnormalities.
  24. History of mental illness, which, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.
  25. Subject with a history of clinically significant head injury, ongoing seizure disorder, chronic tics, or diagnosis or family history of Tourette's syndrome.
  26. Subjects with a history of serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, advanced arteriosclerosis, symptomatic cardiovascular disease, hypertension, or other cardiac problems.
  27. Any history of clinically significant suicidality as assessed by the Investigator based upon clinical history, source documents, or scores on the Columbia-Suicide Severity Rating Scale (C-SSRS).
  28. History or presence of clinically significant hepatic or renal disease.
  29. History of hyperthyroidism.
  30. Difficulty with venous access or unsuitable or unwilling to undergo catheter insertion.
  31. Use of a cytochrome p450 (CYP)2D6-inhibiting drug or a serotonergic drug within 14 days prior to first drug administration in the Qualification Phase.
  32. Consumption of any nutrients known to modulate CYP enzymes activity (e.g., grapefruit or grapefruit juice, pomelo juice, star fruit, or Seville [blood] orange products) within 14 days prior to administration of study medication and during the study (including washout period) until after discharge in the last study period.
  33. A subject who, in the opinion of the Investigator or designee, is considered unsuitable or unlikely to comply with the study protocol for any reason.
  34. A subject who has pending legal charges or is on probation.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    HSK3486 0.1 mg/kg

    HSK3486 (IV bolus over 30 seconds \[+5 seconds\] from a syringe)

    Drug: HSK3486

  • Experimental
    HSK3486 0.125 mg/kg

    HSK3486 (IV bolus over 30 seconds \[+5 seconds\] from a syringe)

    Drug: HSK3486

  • Experimental
    HSK3486 0.15 mg/kg

    HSK3486 (IV bolus over 30 seconds \[+5 seconds\] from a syringe)

    Drug: HSK3486

  • Experimental
    HSK3486 0.175 mg/kg

    HSK3486 (IV bolus over 30 seconds \[+5 seconds\] from a syringe)

    Drug: HSK3486

  • Experimental
    HSK3486 0.2 mg/kg

    HSK3486 (IV bolus over 30 seconds \[+5 seconds\] from a syringe)

    Drug: HSK3486

  • Experimental
    HSK3486 0.225 mg/kg

    HSK3486 (IV bolus over 30 seconds \[+5 seconds\] from a syringe)

    Drug: HSK3486

  • Active comparator
    Propofol 0.5 mg/kg

    Propofol (IV bolus over 30 seconds \[+5 seconds\] from a syringe)

    Drug: propofol

  • Active comparator
    Propofol 0.625 mg/kg

    Propofol (IV bolus over 30 seconds \[+5 seconds\] from a syringe)

    Drug: propofol

  • Active comparator
    Propofol 0.675 mg/kg

    Propofol (IV bolus over 30 seconds \[+5 seconds\] from a syringe)

    Drug: propofol

  • Active comparator
    Propofol 0.725 mg/kg

    Propofol (IV bolus over 30 seconds \[+5 seconds\] from a syringe)

    Drug: propofol

  • Active comparator
    Propofol 0.775 mg/kg

    Propofol (IV bolus over 30 seconds \[+5 seconds\] from a syringe)

    Drug: propofol

  • Placebo comparator
    Placebo

    Intralipid (IV bolus over 30 seconds \[+5 seconds\] from a syringe)

    Drug: Placebo

Interventions

  • HSK3486 for induction of general anesthesia

  • Propofol for induction of general anesthesia

  • DrugPlacebo

    Intralipid

06

What researchers measure

Primary outcomes

  1. Dose Determination for use in part 2

    To determine the doses of IV HSK3486 and propofol for use in Part 2, the abuse potential part of the study

    Time frame: Screening between Day -28 and Day -2; confinement period 3 days in clinic from Day -1 (admission) to 24 hours after study drug administration; follow-up 3 to 7 days after study drug administration

07

Study locations

1 site
  • ICON (LPRA) - Salt Lake
    Salt Lake City, Utah 84124, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Oct 2023, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 11, 2026
StartActual
Aug 16, 2022
Primary completionActual
Oct 3, 2023
CompletionActual
Oct 3, 2023
Last update
Feb 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07404306
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Aug 16, 2022
Primary completion
Oct 3, 2023
Completion
Oct 3, 2023
Last update
Feb 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion